Omicron 时代 SARS-CoV-2 感染患者的造血干细胞移植结果。

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-08-13 DOI:10.1016/j.ijid.2024.107207

Won Jun Choi , Jinhong Lee , Kowoon Choi , Dong Mi Kim , Nayoung Han , Jin-Ho Choi , Jongheon Jung , Hyewon Lee , Jun Yong Choi , Young Ju Choi , Hyeon-Seok Eom , June Young Chun , Eunyoung Lee

{"title":"Omicron 时代 SARS-CoV-2 感染患者的造血干细胞移植结果。","authors":"Won Jun Choi , Jinhong Lee , Kowoon Choi , Dong Mi Kim , Nayoung Han , Jin-Ho Choi , Jongheon Jung , Hyewon Lee , Jun Yong Choi , Young Ju Choi , Hyeon-Seok Eom , June Young Chun , Eunyoung Lee","doi":"10.1016/j.ijid.2024.107207","DOIUrl":null,"url":null,"abstract":"<div><p>Here, we present the outcomes of four patients with COVID-19 who underwent hematopoietic stem cell transplantation (HSCT) at the National Cancer Center in South Korea. Despite concerns about the unfavorable course of COVID-19 in HSCT recipients, none of our patients experienced severe COVID-19. Moreover, extended viral shedding in case 1, lasting over 100 days, was resolved after successful engraftment. Contracting the virus when the host could not mount enough of an immune reaction might result in a paradoxically favorable course. Vaccination, monoclonal antibodies, and antiviral agent usage against COVID-19 might also be effective. We suggest, if necessary, HSCT should not be deferred in COVID-19 patients.</p></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1201971224002789/pdfft?md5=82f109d92a17ac094e85d515e8e14371&pid=1-s2.0-S1201971224002789-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Outcomes of hematopoietic stem cell transplantation in patients with SARS-CoV-2 infection during the Omicron era\",\"authors\":\"Won Jun Choi , Jinhong Lee , Kowoon Choi , Dong Mi Kim , Nayoung Han , Jin-Ho Choi , Jongheon Jung , Hyewon Lee , Jun Yong Choi , Young Ju Choi , Hyeon-Seok Eom , June Young Chun , Eunyoung Lee\",\"doi\":\"10.1016/j.ijid.2024.107207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Here, we present the outcomes of four patients with COVID-19 who underwent hematopoietic stem cell transplantation (HSCT) at the National Cancer Center in South Korea. Despite concerns about the unfavorable course of COVID-19 in HSCT recipients, none of our patients experienced severe COVID-19. Moreover, extended viral shedding in case 1, lasting over 100 days, was resolved after successful engraftment. Contracting the virus when the host could not mount enough of an immune reaction might result in a paradoxically favorable course. Vaccination, monoclonal antibodies, and antiviral agent usage against COVID-19 might also be effective. We suggest, if necessary, HSCT should not be deferred in COVID-19 patients.</p></div>\",\"PeriodicalId\":14006,\"journal\":{\"name\":\"International Journal of Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1201971224002789/pdfft?md5=82f109d92a17ac094e85d515e8e14371&pid=1-s2.0-S1201971224002789-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1201971224002789\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224002789","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在此，我们介绍了在韩国国立癌症中心接受造血干细胞移植（HSCT）的四名 COVID-19 患者的治疗结果。尽管COVID-19在造血干细胞移植受者中的不良病程令人担忧，但我们的患者中没有一人出现严重的COVID-19。此外，病例 1 持续了 100 多天的病毒脱落也在成功移植后消失了。当宿主无法产生足够的免疫反应时感染病毒，可能会导致相反的有利病程。针对 COVID-19 的疫苗接种、单克隆抗体和抗病毒药物也可能有效。我们建议，如有必要，COVID-19 患者不应推迟造血干细胞移植。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes of hematopoietic stem cell transplantation in patients with SARS-CoV-2 infection during the Omicron era

Here, we present the outcomes of four patients with COVID-19 who underwent hematopoietic stem cell transplantation (HSCT) at the National Cancer Center in South Korea. Despite concerns about the unfavorable course of COVID-19 in HSCT recipients, none of our patients experienced severe COVID-19. Moreover, extended viral shedding in case 1, lasting over 100 days, was resolved after successful engraftment. Contracting the virus when the host could not mount enough of an immune reaction might result in a paradoxically favorable course. Vaccination, monoclonal antibodies, and antiviral agent usage against COVID-19 might also be effective. We suggest, if necessary, HSCT should not be deferred in COVID-19 patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.